CENTENNIAL, Colo., January 15, 2015 – Cell>Point announced today positive results following conclusion of a Head and Neck Cancer imaging trial for 99mTc-Oncardia® conducted pursuant to a physician initiated IND study at the University of Chicago Medical Center.
The study imaged patients with squamous cell carcinoma of the head and neck (SCCHN) with technetium-99m- labeled Oncardia® (Ethylenedicysteine-Glucosamine), Cell>Point’s proprietary nuclear imaging product candidate. The purpose of the study was to evaluate and study treatment response for patients with SCCHN. Patients were imaged prior to starting therapy and at 4 and 10 weeks. 99mTc-Oncardia®, as imaged by SPECT/CT, correctly localized in the SCCHN tumor prior to treatment and images at 4 and 10 weeks properly reflected treatment. Cell>Point believes 99mTc-Oncardia® will offer better specificity and better predictive values than those achievable from other imaging modalities in assessing therapeutic response for those patients with locally and advanced head and neck cancer.
Please see attached poster presentation on preliminary results from The University of Chicago.
Cell>Point is a commercialization-stage biopharmaceutical company developing universal molecular imaging agents and molecular therapeutics for the diagnosis, treatment and treatment monitoring of cancer, heart disease, and other diseases. Information on Cell>Point’s product candidates and licenses, recent press releases, and patents and patent filings can be obtained through its website at www.cellpointweb.com. The Company has offices in Centennial, Colo. and Houston, Texas.